IN BRIEF: Solvonis Therapeutics hails US patent from PTSD programme
8th Apr 2026 14:31
Solvonis Therapeutics PLC - London-based biopharmaceutical company, focused on central nervous system disorders - Celebrates second US patent by United States Patent & Trademark Office, covering a further monoamine modulator compound series arising from its proprietary post-traumatic stress disorder discovery programme. The patent, U.S. Patent No. 12,595,269, was issued on Tuesday. On March 31, the company had announced the first such patent, U.S. Patent No. 12,590,077. Read More